EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Viatris's enterprise value is $30,429 Mil.
Viatris's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $15,239 Mil. Therefore, Viatris's EV-to-Revenue for today is 2.00.
The historical rank and industry rank for Viatris's EV-to-Revenue or its related term are showing as below:
VTRS'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.66 Med: 2.49 Max: 5.38
Current: 2
During the past 13 years, the highest EV-to-Revenue of Viatris was 5.38. The lowest was 1.66. And the median was 2.49.
VTRS's EV-to-Revenue is ranked better than 58.75% of 989
companies
in the Drug Manufacturers industry
Industry Median: 2.42
vs VTRS: 2.00
As of today (2024-10-31), Viatris's stock price is $11.60.
Viatris's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $12.65. Therefore, Viatris's PS Ratio for today is 0.92.
Viatris EV-to-Revenue Historical Data
The historical data trend for Viatris's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Viatris's EV-to-Revenue falls into.
Viatris's current Enterprise Value is $30,429 Mil.
Viatris's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $15,239 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris's share price for today is $11.60.
Viatris's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.65.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Viatris's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VTRS has been successfully added to your 